• BGJ398 (NVP-BGJ398): Optimizing FGFR Inhibition in Oncology

  2026-05-03

  BGJ398 (NVP-BGJ398) empowers researchers to precisely dissect FGFR signaling and drive apoptosis induction in cancer cells. This article delivers applied assay workflows, troubleshooting insights, and new interpretation tools based on the latest comparative developmental biology findings.

• Human iPSC Sensory Neurons Model HSV-1 Latency and Reactivat

  2026-05-02

  This study establishes a robust protocol for differentiating human inducible pluripotent stem cells (hiPSCs) into functional sensory neurons and validates their use as an in vitro model for latent infection and reactivation by herpes simplex virus 1 (HSV-1). The model enables mechanistic studies of HSV-1 latency in human neurons, supporting translational research into therapeutic strategies.

• Enhanced In-Vitro Activity of Temafloxacin Versus Gram-Posit

  2026-05-01

  This study systematically evaluates temafloxacin, a fluoroquinolone broad-spectrum antibacterial agent, for its in-vitro efficacy against Gram-positive bacteria from bloodstream infections. The research demonstrates that temafloxacin surpasses older quinolones in potency against Staphylococcus aureus and Streptococcus pneumoniae, highlighting its potential for translational and resistance research.

• Micro- and Nanoplastics Drive Pulmonary Fibrosis via FXR-YAP

  2026-05-01

  This study rigorously compares the pulmonary toxicity of microplastics and nanoplastics of varying polymers and sizes, demonstrating that both particle size and composition critically modulate fibrogenic and inflammatory responses in lung tissue. Mechanistic evidence implicates dysregulation of the FXR-YAP1 axis as a central pathway, with polystyrene nanoplastics exerting the most pronounced effects—findings that refine environmental risk assessment and mechanistic toxicology.

• Differential Shh, Fgf10, and Fgfr2 Expression Shapes Penile

  2026-04-30

  This study dissects species-specific penile development by comparing Shh, Fgf10, and Fgfr2 expression in guinea pigs and mice. The findings clarify mechanisms underlying urethral groove and prepuce formation, with implications for understanding human genital morphogenesis.

• Antimycin A4 as a Precision Metabolic Blocker: Structural In

  2026-04-30

  Explore the multifaceted role of Antimycin A4 as an ATP-citrate lyase inhibitor and mitochondrial research tool. This article uniquely dissects structure–activity relationships and protocol design considerations, offering actionable guidance for advanced energy metabolism studies.

• β-Adrenergic Blockade Impacts Hematopoietic Regeneration Pos

  2026-04-29

  This study demonstrates that nonselective β-adrenergic receptor blockers impair hematopoietic regeneration after hematopoietic cell transplantation (HCT), while β1-selective inhibition does not. The findings have significant implications for the selection of β-blocker regimens in clinical and experimental transplantation settings.

• Tin Mesoporphyrin IX: Precision Inhibition in Heme Oxygenase

  2026-04-29

  Explore how Tin Mesoporphyrin IX (chloride) delivers unparalleled precision in heme oxygenase activity assays, with a focus on its advanced kinetic profile and implications for metabolic disease research. This article reveals unique protocol strategies and bridges fundamental enzymology with translational insights.

• Vidarabine Monohydrate: Expanding Antiviral Assay Frontiers

  2026-04-28

  Explore Vidarabine monohydrate as a unique antiviral research compound. This article reveals its assay-defining solubility and mechanistic specificity, offering guidance not found in existing resources.

• BGJ398 (NVP-BGJ398): Selective FGFR Inhibitor for Oncology R

  2026-04-28

  BGJ398 (NVP-BGJ398) is a potent and selective FGFR1/2/3 inhibitor used to study FGFR-driven malignancies and apoptosis in cancer cells. Its nanomolar potency and selectivity profile enable precise modulation of FGFR signaling in oncology research applications.

• Modeling HSV-1 Latency in Human iPSC-Derived Sensory Neurons

  2026-04-27

  This study establishes a scalable protocol to differentiate human inducible pluripotent stem cells (hiPSCs) into sensory neurons capable of supporting HSV-1 latent infection and reactivation. The work provides a human-specific platform for mechanistic studies of HSV-1 latency and opens avenues for evaluating therapeutic strategies that were previously limited to animal models.

• IL-18-Based Tools Reveal Overlapping Caspase-1 and Caspase-8

  2026-04-27

  This study introduces a novel IL-18 tetrapeptide-based inhibitor, uncovering unexpected substrate and inhibitor specificities shared between inflammatory and apoptotic initiator caspases. The findings reveal that VX-765, while widely used for selective caspase-1 inhibition, also targets caspase-8, informing future assay design and interpretation.

• Z-IETD-FMK: Precision Caspase-8 Inhibition in Cell Death Ass

  2026-04-26

  Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone) enables precise dissection of caspase-8-dependent pathways in apoptosis and immune activation studies. This guide translates recent insights—including the mechanistic bridge to avian pyroptosis—into actionable workflows and troubleshooting strategies for advanced cell death research.

• Targeting Extracellular Vesicle Release in Triple-Negative B

  2026-04-25

  McNamee et al. present a comprehensive evaluation of small molecule inhibitors, including the calpain inhibitor Calpeptin, for suppressing extracellular vesicle (EV) release from triple-negative breast cancer (TNBC) cells. Their findings demonstrate that broad inhibition of EV release can significantly reduce the transmission of aggressive cancer traits, highlighting the potential of EV-targeted approaches in TNBC research.

• Topotecan’s Mechanistic Advances and Implications for Cancer

  2026-04-24

  This review highlights the pharmacological innovation of topotecan, a topoisomerase I inhibitor with a unique DNA-damaging mechanism distinct from alkylating chemotherapeutic agents. The article synthesizes findings on topotecan’s clinical efficacy, toxicity profile, and its evolving role in combination regimens for challenging cancers such as ovarian and small cell lung cancer.

11111 records 1/741 page Next 12345 下5页 Last page